
CLAIMS

1. A pharmaceutical composition comprising a compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof:



(I')

wherein:

Y^1 is CR^a or N;

Y^2 is CR^b or N;

Y^3 is CR^c or N;

provided that only 0 or 1 of Y^1, Y^2 and Y^3 is N and the others are CR^a, CR^b, or CR^c;

R^a, R^b and R^c are each independently selected from hydrogen or halogen;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, 4-6 membered cycloalkyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl; wherein the 4-6 membered cycloalkyloxy is optionally substituted with one, two, or three substituents independently selected from halogen; and wherein the haloC_{1-6}alkoxy is optionally substituted with C_{1-6}alkoxy;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;


R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy and Si(C_{1-6}alkyl)$_3$; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and C_{2-6} alkynyl; and

n is 0, 1, 2, or 3.

2. A pharmaceutical composition according to claim 1 comprising a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, 4-6 membered cycloalkyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl; wherein the 4-6 membered cycloalkyloxy is optionally substituted with one, two, or three substituents independently selected from halogen; and wherein the haloC_{1-6}alkoxy is optionally substituted with C_{1-6}alkoxy;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;


R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy and Si(C_{1-6}alkyl)$_3$; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and C_{2-6} alkynyl; and

n is 0, 1, 2, or 3.

3. A pharmaceutical composition comprising a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 4-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, and haloC_{1-6}alkyl; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl; and

n is 0, 1, 2, or 3.

4. A pharmaceutical composition according to any one of claims 1 to 3 comprising a compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof:

wherein:

Y^1, Y^2 are CH

Y^3 is selected from CH or N;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl;

R^2 and R^3 are independently selected from hydrogen, and hydroxyC_{1-6}alkyl;

R^4 and R^5 are independently selected from hydrogen, a saturated monocyclic 3-5 membered cycloalkyl, haloC_{1-6}alkyl and C_{1-6}alkyl, or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, $Si(C_{1-6}alkyl)_3$ and phenyl, wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkoxy, and haloC_{1-6}alkyl; and

n is 0, 1, or 2.

5. A pharmaceutical composition according to any one of claims 1 to 4 comprising a compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof:

wherein:

Y^1, Y^2 are CH

Y^3 is selected from CH or N;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, or 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl;

R^2 and R^3 are independently selected from hydrogen, and hydroxyC_{1-6}alkyl;


R^4 and R^5 are independently selected from hydrogen, a saturated monocyclic 3-5 membered cycloalkyl, haloC_{1-6}alkyl and hydroxyC_{1-6}alkyl,

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, $Si(C_{1-6}alkyl)_3$ and phenyl, wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, cyano, hydroxy, haloC_{1-6}alkoxy and haloC_{1-6}alkyl; and

n is 0, 1, or 2.


6. A pharmaceutical composition according to any one of claims 1-5, wherein the compound of formula (I') or (I) excludes compounds in which all of the following applies:

R^1 is



,

R^6 is:



or ,

n is 2, and R^4 and R^5 are (i) all hydrogen or (ii) within the first pair of R^4 and R^5 both are hydrogen and within the second pair of R^4 and R^5 one is hydrogen and the other one is hydroxy.

7. A pharmaceutical composition according to any one of claims 1-6, wherein the compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.


8. A pharmaceutical composition according to any one of claims 1-7, wherein the compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, wherein R^6 is selected from a saturated monocyclic 3-6 membered cycloalkyl, a 7-10 membered bicycylic fused cycloalkyl, a 4-10 membered bridged cycloalkyl, a saturated monocyclic 3-6 membered cycloalkyl group, a 7-10 membered bicycylic fused cycloalkyl, phenyl, $Si(C_{1\text{-}6}alkyl)_3$ and a halo$C_{1\text{-}6}$alkyl.

9. A pharmaceutical composition according to any one of claims 1-8, wherein the compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof, wherein R^6 is selected from a saturated monocyclic 3-6 membered cycloalkyl, a 7-10 membered

bicycylic fused cycloalkyl, a 4-10 membered bridged cycloalkyl, a saturated monocyclic 3-6 membered cycloalkyl group, and a 7-10 membered bicycylic fused cycloalkyl.

10. A pharmaceutical composition according to any one of claims 1-9, wherein the pharmaceutical composition further comprises one or more pharmaceutical excipients.

11. A compound of formula (I'), or a solvate or a pharmaceutically acceptable salt thereof:



(I')

wherein:

Y^1 is CR^a or N;

Y^2 is CR^b or N;

Y^3 is CR^c or N;

provided that only 0 or 1 of Y^1, Y^2 and Y^3 is N and the others are CR^a, CR^b, or CR^c;

R^a, R^b and R^c are each independently selected from hydrogen or halogen;

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, 4-6 membered cycloalkyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl; wherein the 4-6 membered cycloalkyloxy is optionally substituted with one, two, or three substituents independently selected from halogen; and wherein the haloC_{1-6}alkoxy is optionally substituted with C_{1-6}alkoxy;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;


R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy and Si(C_{1-6}alkyl)$_3$; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and C_{2-6} alkynyl; and

n is 0, 1, 2, or 3.

12. A compound according to claim 11 wherein the compound is of formula (I), or a solvate or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, 4-6 membered cycloalkyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl; wherein the 4-6 membered cycloalkyloxy is optionally substituted with one, two, or three substituents independently selected from halogen; and wherein the haloC_{1-6}alkoxy is optionally substituted with C_{1-6}alkoxy;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;


R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, haloC_{1-6}alkyl, haloC_{1-6}alkoxy and Si(C_{1-6}alkyl)$_3$; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, haloC_{1-6}alkyl and C_{2-6} alkynyl; and

n is 0, 1, 2, or 3.

13. A compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from a 4-6 membered heterocycloalkyl, cyano, haloC_{1-6}alkoxy, C_{1-6}alkoxy, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, cyanoC_{1-6}alkoxy, and 5 membered heteroaryl; wherein the heterocycloalkyl, heterocyclyloxy, and heteroaryl are optionally substituted with one C_{1-6}alkyl, or haloC_{1-6}alkyl;

R^2 and R^3 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, and hydroxyC_{1-6}alkyl; or

R^2 and R^3 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^4 and R^5 are independently selected from hydrogen, deuterium, C_{1-6}alkyl, saturated monocyclic 3-5 membered cycloalkyl, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl, and hydroxy; or

R^4 and R^5 together with the one carbon atom to which they are attached form a saturated monocyclic 3-5 membered cycloalkyl;

R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 4-10 membered cycloalkyl, phenyl, C_{1-6}alkyl, and haloC_{1-6}alkyl; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl; and

n is 0, 1, 2, or 3.

14. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11 to 13 wherein:

Y^1, Y^2 are CH;

Y^3 is selected from CH or N.

15. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11 to 14, wherein R^1 is selected from cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, a 4-6 membered heterocyclyloxy, halogen, haloC_{1-6}alkyl, C_{3-5}cycloalkylC_{1-6}alkoxy, and cyanoC_{1-6}alkoxy; wherein the heterocyclyloxy and cycloakylalkoxy are optionally substituted with one C_{1-6}alkyl or haloC_{1-6}alkyl.

16. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11 to 15, wherein R^1 is selected from cyano, haloC_{1-6}alkoxy, haloC_{1-6} alkylthio, and haloC_{1-6}alkyl.

17. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11 to 15, wherein R^1 is selected from cyano, CHF_2O-, CHF_2S-, CH_3CF_2O-, CH_3CFHCH_2O-, CF_3CH_2O-, CH_3CF_2-, CHF_2-, and CF_3-.

18. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 17, wherein R^1 is selected from CHF_2O-, CHF_2S-, CH_3CF_2O-, CH_3CFHCH_2O-, and CF_3CH_2O-.

19. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 17 or 18, wherein R^1 is CHF_2O- or CH_3CF_2O-.

20. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11 to 14, wherein R^1 is 5 membered heteroaryl selected from pyrazolyl and imidazolyl which are optionally substituted with one, two, or three substituents independently selected from halogen or halo$C_{1\text{-}6}$alkyl.

21. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 20, wherein R^1 is unsubstituted pyrazolyl or unsubstituted imidazolyl.

22. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 11 to 21, wherein (i) both R^2 and R^3 are hydrogen, or (ii) one of R^2 and R^3 is hydrogen and the other one is hydroxy$C_{1\text{-}6}$alkyl.

23. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 22, wherein one of R^2 and R^3 is hydrogen and the other one is hydroxy$C_{1\text{-}6}$alkyl selected from $HOCH_2$-, $HOCH_2CH_2$-, $HOCH_2CH_2CH_2$-, and $HOCH_2CH_2CH_2CH_2$-.

24. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 23, wherein the hydroxy$C_{1\text{-}6}$alkyl is $HOCH_2$- or $HOCH_2CH_2$-.

25. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 22, wherein both R^2 and R^3 are hydrogen.

26. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11 to 25, wherein n is 0 or 1.

27. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 26, wherein n is 0.

28. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 26, wherein n is 1.

29. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 28, wherein n is 1 and (i) both R^4 and R^5 are hydrogen, (ii) one of R^4 and R^5 is hydrogen and the other one is C_{1-6}alkyl, haloC_{1-6}alkyl, a saturated monocyclic 3-5 membered cycloalkyl, or C_{1-6}alkoxy.

30. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 29, wherein one of R^4 and R^5 is hydrogen and the other one is a methyl (CH_3-) or methoxy (CH_3O-).

31. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 29, wherein one of R^4 and R^5 is hydrogen and the other one is a trifluoromethyl (-CF_3) or difluoromethyl (-CHF_2).

32. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 29, wherein the saturated monocyclic 3-5 membered cycloalkyl is unsubstituted cyclopropyl.

33. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 29, wherein n is 1 and both R^4 and R^5 are hydrogen.

34. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-29, wherein R^4 and R^5, together with the one carbon atom to which they are attached, form cyclopropyl.

35. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 11-34, wherein R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, a 3-10 membered cycloalkyl, C_{1-6}alkyl, haloC_{1-6}alkyl, Si(C_{1-6}alkyl)$_3$ and phenyl; wherein the heterocycloalkyl, heteroaryl, cycloalkyl, or phenyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl.

36. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 11-35, wherein R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, and a 3-10 membered cycloalkyl; wherein the heterocycloalkyl, heteroaryl, or cycloalkyl are optionally substituted with one, two, or three substituents independently selected from halogen, C_{1-6} alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, cyano, oxo, hydroxy, hydroxyC_{1-6}alkyl, and haloC_{1-6}alkyl.

37. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 36, wherein R^6 is optionally substituted with one, two, or three substituents independently selected from Cl-, F-, CH_3-, CH_2F-, CF_3-, $(CH_3)_2CF$-, cyclopropyl, and CH_3O-, CF_3O-, CHF_2O-, cyano, and hydroxy.

38. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 37, wherein R^6 is optionally substituted with one, two, or three substituents independently selected from Cl-, F-, CH_3-, CF_3-, cyclopropyl, CH_3O-, CF_3O- and CHF_2O- .

39. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 37 or 38, wherein R^6 is optionally substituted with one, two, or three substituents independently selected from F-, CF_3-, CF_3O- and CHF_2O-.

40. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 35-39, wherein R^6 is selected from:

a) a 5-12 membered heterocycloalkyl, which heterocycloalkyl is selected from a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom; a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom; and a 7-10 membered bridged heterocycloalkyl, wherein the bridge comprises an O-atom;

b) a 6 membered heteroaryl;

c) a 3-10 membered cycloalkyl selected from a saturated monocyclic 3-6 membered cycloalkyl, a 6 membered cycloalkenyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings;

d) phenyl;

e) $C_{1\text{-}6}$alkyl;

f) halo$C_{1\text{-}6}$alkyl;

g) Si($C_{1\text{-}6}$alkyl)$_3$; and

optionally substituted according to any one of claims 35-39.

41. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 40, wherein R^6 is selected from:

a) a 5-12 membered heterocycloalkyl, which heterocycloalkyl is selected from a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom; a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom; and a 7-10 membered bridged heterocycloalkyl, wherein the bridge comprises an O-atom;

b) a 6 membered heteroaryl; and

c) a 3-10 membered cycloalkyl selected from a saturated monocyclic 3-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings.


42. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 35-41, wherein R^6 is selected from:


dihydrochromenyl, cyclopentyl, phenyl, cyclohexyl, bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, cyclohexenyl, cyclobutyl, tert-butyl, bicyclo[2.2.2]octanyl, $(CH_3)_2CF$-, CHF_2-, $Si(CH_3)_3$, bicyclo[3.1.0]hexanyl, oxolanyl, octahydropentalenyl, hexahydrocyclopenta[b]furanyl, pyrazinyl, pyridinyl, and pyrimidinyl.


43. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 35-42, wherein R^6 is selected from:

dihydrochromenyl, cyclopentyl, phenyl, cyclohexyl, bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, cyclohexenyl, cyclobutyl, bicyclo[2.2.2]octanyl, bicyclo[3.1.0]hexanyl, oxolanyl, octahydropentalenyl, hexahydrocyclopenta[b]furanyl, pyrazinyl, pyridinyl, and pyrimidinyl.

44. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 35-43, wherein R^6 is selected from:








and

45. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 44, wherein R^6 is selected from:



and .

46. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 35-45, wherein R^1 is selected from CHF_2O-, unsubstituted pyrazolyl, unsubstituted imidazolyl, CH_3O-, $(CH_3)CF_2$-, CN-, CHF_2-, CF_3-, CF_3CH_2O-, CH_3CFHCH_2O-, CF_2H-S-, R^2 and R^3 are hydrogen, n is 0 or 1, (i) R^4 and R^5 are hydrogen, or (ii) one of R^4 and R^5 is hydrogen and the other is cyclopropyl, or (iii) one of R^4 and R^5 is hydrogen and the other is selected from CF_3-, CHF_2, and CH_2F or (iv) R^4 and R^5 together with the one carbon atom to which they are attached, form cyclopropyl, and R^6 is selected from a 5-12 membered heterocycloalkyl which heterocycloalkyl is a bicyclic edge-

to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom, a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom, a 7-10 membered bridged heterosystem, wherein the bridge comprises an O-atom, a 6 membered heteroaryl; and a 3-10 membered cycloalkyl selected from cyclopropyl, a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings, all optionally substituted according to any one of claims 35-39 and 44-45.

47. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 46, wherein R^1 is selected from CF_3CH_2O-, CHF_2O- or unsubstituted imidazolyl, R^2 and R^3 are hydrogen, n is 0 or 1, (i) R^4 and R^5 are hydrogen, or (ii) one of R^4 and R^5 are hydrogen and the other is cyclopropyl, or (iii) one of R^4 and R^5 is hydrogen and the other is selected from CF_3-, CHF_2, and CH_2F, or (iii) R^4 and R^5 together with the one carbon atom to which they are attached, form cyclopropyl, and R^6 is selected from a 5-12 membered heterocycloalkyl which heterocycloalkyl is a bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom, a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom, a 7-10 membered bridged heterosystem, wherein the bridge comprises an O-atom; a 6 membered heteroaryl; and a 3-10 membered cycloalkyl selected from cyclopropyl, a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings, all optionally substituted according to any one of claims 34-38 and 43-44.

48. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 46 or 47, wherein R^1 is selected from CF_3CH_2O-, CHF_2O- and unsubstituted imidazolyl, R^2 and R^3 are hydrogen, n is 0; and R^6 is selected from a 5-12 membered heterocycloalkyl which heterocycloalkyl is a bicyclic edge-to-edge fused heterocycloalkyl comprising one aliphatic and one aromatic ring, wherein one ring comprises one O-atom, a 7-10 membered bicyclic edge-to-edge fused heterocycloalkyl comprising two aliphatic rings, wherein the one ring comprises one O-atom or one N-atom, a 7-10 membered bridged heterosystem, wherein the bridge comprises an O-atom; a 6 membered heteroaryl; and a 3-10 membered cycloalkyl selected from cyclopropyl, a saturated monocyclic 4-6

membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings; all optionally substituted according to any one of claims 34-38 and 43-44.


49. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 46-48, wherein R^1 is CF_3CH_2O-, or CHF_2O- and R^6 is substituted with one or two F- or CF_3-, or R^6 is CF_3-.





50. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 49, wherein R^1 is CHF_2O- and R^6 is selected from a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings; all substituted with one or two F- or CF_3-.






51. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 35-49 wherein R^1 is CHF_2O-, n is 0 or 1, and R^6 is selected from a 5-12 membered heterocycloalkyl, a 6 membered heteroaryl, and a 4-10 membered cycloalkyl; all substituted with substituted with one or two F- or CF_3-.





52. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to 51, wherein R^6 is selected from a saturated monocyclic 4-6 membered cycloalkyl, a 4-10 membered bridged cycloalkyl, and a 7-10 membered bicyclic edge-to-edge fused cycloalkyl comprising two aliphatic rings; all substituted with one or two F- or CF_3-.






53. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-52, or a pharmaceutical composition according to any one of claims 1-9, wherein the compound is selected from:





Example	**Name**	**Structure**
1	1-[(4R)-3,4-dihydro-2H-chromen-4-yl]-3-[(2-pyrazol-1-	





Example	Name	Structure
	ylpyridin-4-yl)methyl]urea	
2	1-cyclopentyl-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
4	1-(3-chlorophenyl)-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
5	1-[(2-cyanopyridin-4-yl)methyl]-3-(2,4,4-trimethylcyclohexyl)urea	
6	1-[(2-pyrazol-1-ylpyridin-4-yl)methyl]-3-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentanyl]urea	





Example	Name	Structure
7	1-[(2-pyrazol-1-ylpyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
8	1-(3-cyclopropylcyclohexyl)-3-[(2-imidazol-1-ylpyridin-4-yl)methyl]urea	
9	1-[(2-imidazol-1-ylpyridin-4-yl)methyl]-3-(2,4,4-trimethylcyclohexyl)urea	
10	1-[2-(cyclohexen-1-yl)ethyl]-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
12	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-	






Example	Name	Structure
	(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
13	1-(cyclobutylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
14	1-[(2-methoxypyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
15	1-[(1S,2S,4R)-2-bicyclo[2.2.1]heptanyl]-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	
16	1-[(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-3-[(2-pyrazol-1-ylpyridin-4-yl)methyl]urea	





Example	Name	Structure
17	1-(1-cyclobutylethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
18	1-(4,4-dimethylcyclohexyl)-3-[[2-(oxetan-3-yloxy)pyridin-4-yl]methyl]urea	
20	1-cyclopentyl-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
21	1-(cyclobutylmethyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
22	1-(3-chlorophenyl)-3-[[2-(difluoromethoxy)	






Example	Name	Structure
	pyridin-4-yl]methyl]urea	
23	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(4R)-3,4-dihydro-2H-chromen-4-yl]urea	
24	1-[1-(2-bicyclo[2.2.1]heptanyl)ethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
25	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,6-dimethylcyclohexyl)urea	
26	1-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-3-[[2-[4-(trifluoromethyl)imidazol-1-	




Example	Name	Structure
	yl]pyridin-4-yl]methyl]urea	
27	1-[(2-bromopyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
28	1-[[2-(1,3-oxazol-5-yl)pyridin-4-yl]methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
29	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,2-dimethylpropyl)urea	
31	1-(1-bicyclo[1.1.1]pentanylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	






Example	Name	Structure
32	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]urea	
33	1-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
34	1-[(2-cyanopyridin-4-yl)methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	
35	1-[[2-(difluoromethyl)pyridin-4-yl]methyl]-3-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]urea	





Example	Name	Structure
36	1-[rac-(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-3-[[2-(trifluoromethyl)pyridin-4-yl]methyl]urea	
37	1-(4,4-dimethylcyclohexyl)-3-[(2-imidazol-1-ylpyridin-4-yl)methyl]urea	
38	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1-methoxycyclobutyl)methyl]urea	
39	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2-fluoro-2-methylpropyl)urea	
40	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1-	





Example	Name	Structure
	fluorocyclobutyl) methyl]urea	
41	1-(cyclobutylmethyl)-3-[[2-[4-(trifluoromethyl)imidazol-1-yl]pyridin-4-yl]methyl]urea	
42	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
43	1-cyclopentyl-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
44	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[1-(2,2-dimethylpropyl)cyclopropyl]urea	




Example	Name	Structure
45	1-cyclobutyl-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
46	1-(cyclopentylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
47	1-(1-bicyclo[1.1.1]pentanyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
48	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
49	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methoxy-1-	





Example	Name	Structure
	bicyclo[1.1.1]pentanyl)urea	
50	1-(1-cyclobutylcyclopropyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
54	1-[[2-(cyclobutylmethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
55	1-[[2-(cyclopropylmethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	





Example	Name	Structure
56	1-[[2-(2,2-difluoroethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
57	1-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
58	1-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]-3-[[2-(trifluoromethyl)pyridin-4-yl]methyl]urea	
59	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(trifluoromethyl)cyclopentyl]urea	
60	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-	





Example	Name	Structure
	ethylcyclobutyl)urea	
62	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[3-(trifluoromethyl)cyclobutyl]methyl]urea	
63	1-[[2-(cyanomethoxy)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
64	1-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
65	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methylcyclobutyl)urea	





Example	Name	Structure
66	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-ethynylcyclobutyl)urea	
67	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-((1*r*,3*r*)-3-fluorocyclobutyl)urea	
68	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[4-(trifluoromethyl)-1-bicyclo[2.2.2]octanyl]urea	
71	1-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]-3-[[3-(trifluoromethyl)c	





Example	Name	Structure
	yclobutyl]methyl] urea	
73	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[rac-(1R,5R)-6,6-difluoro-2-bicyclo[3.1.0]hexanyl]urea	
74	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[rac-(1R,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]urea	
75	1-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	




Example	Name	Structure
76	1-[(1R,3aR,6aR)-1,2,3,3a,4,5,6,6a-octahydropentalen-1-yl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
77	1-(3-cyclopropylcyclobutyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
78	1-(1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
79	1-[rac-(1R,3S)-3-(trifluoromethyl)cyclopentyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	




Example	Name	Structure
81	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-hydroxy-3,3-dimethylcyclobutyl]urea	
82	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-fluoro-2-hydroxy-1-bicyclo[2.2.2]octanyl)urea	
83	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methoxyphenyl)urea	
84	1-(6-chloropyridin-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
85	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
87	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[3-(1r,3r)-(trifluoromethyl)cyclobutyl]methyl]urea	
88	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-(2-fluoropropoxy)pyridin-4-yl]methyl]urea	
89	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(3-fluorocyclobutyl)methyl]urea	




Example	Name	Structure
90	1-(4,4-difluorocyclohexyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
91	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-[(1*r*,3*r*)-3-(trifluoromethyl)cyclobutyl]urea	
92	1-(3-chlorophenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
93	1-(3,3-difluorocyclopentyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
95	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2-hydroxy-3,3-dimethylbutyl)urea	
96	1-(4-chloropyrimidin-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
97	1-(3-chlorophenyl)-3-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	
98	1-(6-chloropyrazin-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
99	1-[rac-(1R,2S)-2-hydroxy-3,3-dimethylcyclobutyl]-3-[[2-[4-(trifluoromethyl)imidazol-1-yl]pyridin-4-yl]methyl]urea	
100	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,3s)-3-hydroxy-3-(trifluoromethyl)cyclobutyl]urea	
101	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2R)-2-hydroxy-5,5-dimethylcyclohexyl]urea	





Example	Name	Structure
102	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S,4S)-7-oxabicyclo[2.2.1]heptan-2-yl]urea	
103	1-[(1S,3aS,6aS)-1,2,3,3a,4,5,6,6a-octahydropentalen-1-yl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
105	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(3aR,6aS)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]urea	




Example	Name	Structure
106	1-(1-cyclopropyl-2,2,2-trifluoroethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
107	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S,4S,6R)-6-hydroxy-2-bicyclo[2.2.1]heptanyl]urea	
108	1-(3,3-difluorocyclobutyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
109	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3-	





Example	Name	Structure
	dimethylbutyl)urea	
110	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[1-(2,2,2-trifluoroethyl)cyclopropyl]urea	
111	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6S,7R)-7-hydroxy-6-bicyclo[3.2.0]heptanyl]urea	
112	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(2R,3aS,6aS)-6a-(hydroxymethyl)-2,3,3a,4,5,6-hexahydro-1H-pentalen-2-yl]urea	





Example	Name	Structure
113	1-(2,2-difluorocyclopentyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
114	1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
115	1-[(1R)-3,3-difluorocyclopentyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
116	1-[(1S)-3,3-difluorocyclopentyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
117	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-3-hydroxypropyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
118	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-hydroxycyclopentyl]urea	
119	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3,3-trifluoro-2-methoxypropyl)urea	
120	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[rac-(3aR,6aR)-2,3,3a,4,5,6-hexahydrocyclope	




Example	Name	Structure
	nta[b]furan-6a-yl]methyl]urea	
121	1-[[2-(2,2-difluoropropoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
122	1-[[2-(2,2-difluoropropoxy)pyridin-4-yl]methyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
123	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-fluorocyclobutyl]urea	
125	1-[cyclobutyl(dideuterio)methyl]-3-[[2-	




Example	Name	Structure
	(difluoromethoxy) pyridin-4-yl]methyl]urea	
126	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-(3-methylphenyl)urea	
128	1-[(2-methoxypyridin-4-yl)methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
129	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[(2-methoxypyridin-4-yl)methyl]urea	





Example	Name	Structure
131	1-(1-bicyclo[2.2.2]octanyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
132	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[3-(fluoromethyl)phenyl]urea	
133	1-[(1R,2R,5R)-6,6-difluoro-2-bicyclo[3.1.0]hexanyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
134	1-[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
135	1-[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
136	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[3-(difluoromethyl)cyclobutyl]urea	
137	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,3s)-3-(difluoromethyl)cyclobutyl]urea	
138	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(trifluoromethyl)cyclohexyl]urea	




Example	Name	Structure
139	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S)-3-oxo-8-bicyclo[3.2.1]octanyl]urea	
140	1-[(1S)-3,3-difluorocyclohexyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
142	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3-difluoro-1-methylcyclopentyl)urea	
143	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4,4-difluoro-1-	





Example	Name	Structure
	methylcyclohexyl) urea	
144	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[(1S,3R)-3-(trifluoromethyl)cyclopentyl]urea	
145	1-(3-chlorophenyl)-3-[(1R)-2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
146	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[(1R,3S)-3-(trifluoromethyl)cyclopentyl]urea	





Example	Name	Structure
147	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[2-hydroxy-2-(trifluoromethyl)cyclohexyl]urea	
148	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2R)-2-hydroxy-2-methylcyclohexyl]urea	
149	1-[(1R)-3,3-difluorocyclohexyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
150	1-(3-chloro-2-fluorophenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
151	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-[(2R)-2-fluoropropoxy]pyridin-4-yl]methyl]urea	
152	1-(1-cyclobutyl-2,2,2-trifluoroethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
153	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(trifluoromethyl)pyridin-4-yl]methyl]urea	



Example	Name	Structure
154	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2R)-4,4-difluoro-2-hydroxycyclohexyl]urea	
156	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-[(2S)-2-fluoropropoxy]pyridin-4-yl]methyl]urea	
157	1-(3,3-difluorocyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
159	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	

Example	Name	Structure
160	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(2-fluoropropoxy)pyridin-4-yl]methyl]urea	
161	1-(5-chloropyridin-3-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
162	1-((1r,3r)-3-fluorocyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	


Example	Name	Structure
163	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-((1r,3r)-3-methylcyclobutyl)urea	
164	1-(3-chlorophenyl)-3-[[2-(fluoromethoxy)pyridin-4-yl]methyl]urea	
165	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,4R)-5,5-difluoro-2-bicyclo[2.2.1]heptanyl]urea	
166	1-(5-cyclopropyloxolan-3-yl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
168	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
169	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]urea	
170	1-[(1R,5S,6R)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
171	1-[1-(3,3-difluorocyclobutyl)cyclopropyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
172	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6R)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]urea	
173	1-(2,2-difluorocyclopropyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
174	1-[(1S,5R,6S)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
175	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[1-(trifluoromethyl)cyclopropyl]urea	





Example	Name	Structure
176	1-[[2-(fluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6R)-2,2-difluoro-6-bicyclo[3.1.0]hexanyl]urea	
177	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)cyclopropyl] urea	





54. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-52, or a pharmaceutical composition according to any one of claims 1-9, wherein the compound is selected from:




Example	Name	Structure
178	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[3-(trifluoromethyl)-1-	





Example	Name	Structure
	bicyclo[1.1.1]pentanyl]urea	
179	1-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
180	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
181	1-[(3,3-difluorocyclobutyl)methyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
182	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3-methyl-1-bicyclo[1.1.1]pentanyl)urea	






Example	Name	Structure
183	1-[[2-(2-fluoropropoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
184	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1S,2S)-2-hydroxy-2-methylcyclopentyl]urea	
185	1-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
186	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,4-difluorophenyl)urea	





Example	Name	Structure
187	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-hydroxy-3-(trifluoromethyl)cyclopentyl]urea	
188	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,3-dimethylcyclobutyl)urea	
189	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1R,3r,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]urea	
190	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2s,3aR,6aS)-1,2,3,3a,4,5,6,6a-	





Example	Name	Structure
	octahydropentalen-2-yl]urea	
191	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[1-(difluoromethyl)cyclobutyl]methyl]urea	
192	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(3,4-dihydro-2H-chromen-3-yl)urea	
193	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(difluoromethyl)cyclopentyl]urea	
194	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-1-methyl-3-	





Example	Name	Structure
	(trifluoromethyl)cyclobutyl]urea	
195	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2r,3aR,6aS)-5,5-difluoro-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]urea	
196	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5R)-2-bicyclo[3.2.0]heptanyl]urea	
197	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S)-3,3-difluoro-8-bicyclo[3.2.1]octanyl]urea	





Example	Name	Structure
198	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,3s)-3-(trifluoromethyl)cyclobutyl]urea	
199	1-[[2-[(2R)-2-fluoropropoxy]pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
200	1-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
201	1-[[2-(2,2-difluoropropoxy)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	





Example	Name	Structure
202	1-[[2-[(2S)-2-fluoropropoxy]pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
203	1-(3-chlorophenyl)-3-[[2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl]methyl]urea	
204	1-[[2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
205	1-(4-fluoro-3-methylphenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
206	1-[[2-(difluoromethoxy)pyridin-4-	





Example	Name	Structure
	yl]methyl]-3-[(1R,3R)-3-(trifluoromethyl)cyclopentyl]urea	
207	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1S,3S)-3-(trifluoromethyl)cyclopentyl]urea	
208	1-(4-fluoro-1-bicyclo[2.2.2]octanyl)-3-[[2-(fluoromethoxy)pyridin-4-yl]methyl]urea	
209	1-[[2-(3,3-difluorocyclobutyl)oxypyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
210	1-[(1-fluorocyclobutyl)methyl]-3-[[2-(2,2,2-trifluoroethoxy)py	





Example	Name	Structure
	ridin-4-yl]methyl]urea	
211	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1s,4s)-4-(trifluoromethyl)cyclohexyl]urea	
212	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2-trimethylsilylethyl)urea	
213	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-(4-fluoro-1-bicyclo[2.2.2]octanyl)urea	
214	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-[(1r,3r)-3-	





Example	Name	Structure
	(trifluoromethyl)cyclobutyl]urea	
215	1-[[6-(2,2,2-trifluoroethoxy)pyridazin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
216	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
217	1-[[2-(2,2-difluoroethoxy)pyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
218	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(6-methylpyridin-2-yl)urea	





Example	Name	Structure
219	1-[[2-(difluoromethoxy)-3-fluoropyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
220	1-(3-chlorophenyl)-3-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]urea	
221	1-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]-3-[[2-(1,1,1-trifluoropropan-2-yloxy)pyridin-4-yl]methyl]urea	
222	1-(7,7-difluoro-3-bicyclo[4.1.0]heptanyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
223	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[[2-(1,1,1-trifluoropropan-2-yloxy)pyridin-4-yl]methyl]urea	
224	1-[[2-(3,3-difluorocyclobutyl)oxypyridin-4-yl]methyl]-3-(3-fluoro-1-bicyclo[1.1.1]pentanyl)urea	
225	1-[[2-(2,3-difluoropropoxy)pyridin-4-yl]methyl]-3-[rac-(1R,3S)-3-(trifluoromethyl)cyclopentyl]urea	
226	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[2-(trifluoromethyl)oxan-4-yl]urea	






Example	Name	Structure
227	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1-fluorocyclopentyl)methyl]urea	
228	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(1,1,1,3,3,3-hexafluoropropan-2-yl)urea	
229	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[1-(trifluoromethyl)cyclopropyl]methyl]urea	
230	1-[(1R)-1-(3,3-difluorocyclobutyl)-2,2-difluoroethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
231	1-(3-chlorophenyl)-3-[[2-(1,1-difluoroethyl)pyridin-4-yl]methyl]urea	
232	1-[3-(fluoromethyl)phenyl]-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
233	1-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]-3-(3-methylphenyl)urea	
234	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(3R,4S)-3,4-difluorocyclopentyl]urea	





Example	Name	Structure
235	1-(3-cyclopropylcyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
236	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S,4S)-6,6-difluoro-2-bicyclo[2.2.1]heptanyl]urea	
237	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[[1-(trifluoromethyl)cyclobutyl]methyl]urea	
238	1-[(1R,3s,5S)-6,6-difluoro-3-bicyclo[3.1.0]hexanyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	






Example	Name	Structure
239	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[(1S,3S)-3-fluorocyclopentyl] urea	
240	1-[1-[2-(difluoromethoxy) pyridin-4-yl]-2-hydroxyethyl]-3-(3,4-difluorophenyl)urea	
241	1-[(1R)-1-cyclobutyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	
242	1-[(1S)-1-cyclobutyl-2,2,2-trifluoroethyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	





Example	Name	Structure
243	1-[[2-(difluoromethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
244	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,5-difluorophenyl)urea	
245	1-(2,5-difluorophenyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
246	1-[1-(1-bicyclo[1.1.1]pentanyl)cyclopropyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	





Example	Name	Structure
247	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,3-difluorophenyl)urea	
248	1-(2,3-difluorophenyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
249	1-(3,4-difluorophenyl)-3-[[2-(fluoromethoxy)pyridin-4-yl]methyl]urea	
250	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1R,3S)-3-(trifluoromethyl)cyclohexyl]urea	
251	1-[dideuterio-[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-	





Example	Name	Structure
	fluoro-1-bicyclo[2.2.2]octanyl)urea	
252	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[3,3,3-trifluoro-2-(trifluoromethyl)propyl]urea	
253	1-(dicyclopropylmethyl)-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
254	1-[1-(3,3-difluorocyclobutyl)cyclopropyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
255	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,2S)-2-	





Example	Name	Structure
	(trifluoromethyl)cyclobutyl]urea	
256	1-(3,5-difluorophenyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
257	1-[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
258	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[5-(trifluoromethyl)oxolan-3-yl]urea	
259	1-(3-chlorophenyl)-3-[1-[2-(2,2-difluoroethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	





Example	Name	Structure
260	1-[[2-(difluoromethylsulfanyl)pyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
261	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(4-fluoro-3-methylphenyl)urea	
262	1-[3-(difluoromethoxy)phenyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
263	rel-1-(3-chlorophenyl)-3-[(1R)-1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	
264	1-[3-(difluoromethoxy)cyclopentyl]-3-[[2-	





Example	Name	Structure
	(difluoromethoxy) pyridin-4-yl]methyl]urea	
265	1-[(1s,3s)-3-(difluoromethoxy) cyclobutyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	
266	1-[(1r,4r)-4-(difluoromethoxy) cyclohexyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	
267	1-[[2-(difluoromethoxy) pyridin-4-yl]methyl]-3-[3-(trifluoromethoxy) cyclobutyl]urea	
268	1-[2-(difluoromethoxy) propyl]-3-[[2-(difluoromethoxy) pyridin-4-yl]methyl]urea	





Example	Name	Structure
269	1-((1s,3s)-3-fluorocyclobutyl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
270	1-(3-chloro-2-fluorophenyl)-3-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]urea	
271	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[rac-(1R,5S,6R)-3,3-difluoro-6-bicyclo[3.1.0]hexanyl]urea	
272	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-(2,3,4-trifluorophenyl)urea	



Example	Name	Structure
273	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2S)-1,1,1,4,4,4-hexafluorobutan-2-yl]urea	
274	1-(3,4-difluorophenyl)-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	
275	1-(3-chlorophenyl)-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	
276	1-[rac-(1R,3S)-3-(trifluoromethyl)cyclohexyl]-3-[[2-(2,2,2-trifluoroethyl)pyridin-4-yl]methyl]urea	

Example	Name	Structure
277	1-[[2-(difluoromethoxy)-5-fluoropyridin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
278	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-[(3S)-3,4-dihydro-2H-chromen-3-yl]urea	
279	1-[[6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
280	1-[1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxyethyl]-3-(3-methylphenyl)urea	

Example	Name	Structure
281	1-[[2-(1,1,1-trifluoro-3-methoxypropan-2-yl)oxypyridin-4-yl]methyl]-3-[3-(trifluoromethyl)cyclobutyl]urea	
282	1-[[6-(difluoromethoxy)pyrimidin-4-yl]methyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
283	1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-3-[2-hydroxy-1-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]ethyl]urea	
284	1-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]-3-[[1-(trifluoromethyl)cyclopropyl]methyl]urea	

Example	Name	Structure
285	1-(1,1,1,3,3,3-hexafluoropropan-2-yl)-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
286	1-[(2R)-1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxypropyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
287	1-[(2S)-1-[2-(difluoromethoxy)pyridin-4-yl]-2-hydroxypropyl]-3-[(1r,3r)-3-(trifluoromethyl)cyclobutyl]urea	
288	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(1R,3S)-3-(trifluoromethoxy)cyclopentyl]urea	


Example	Name	Structure
289	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[2-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]urea	
290	1-[2-(3-fluoro-1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
291	1-[2-(1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]-3-[[2-(difluoromethoxy)pyridin-4-yl]methyl]urea	
292	1-[2-(1-bicyclo[1.1.1]pentanyl)-2-hydroxyethyl]-3-[[2-(2,2,2-	


Example	Name	Structure
	trifluoroethoxy)pyridin-4-yl]methyl]urea	
293	1-[(1r,3r)-3-(difluoromethyl)cyclobutyl]-3-[[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methyl]urea	
294	1-[[2-(difluoromethoxy)pyridin-4-yl]methyl]-3-[(2R)-1,1,1,4,4,4-hexafluorobutan-2-yl]urea	


55. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-54, or a pharmaceutical composition according to any one of claims 1-10, wherein R^1 is CHF_2O- and R^6 is substituted with one or two F-.


56. A compound as set out in any one of Tables 1-9 herein or a solvate or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound as set out in any one of Tables 1-9 herein or a solvate or a pharmaceutically acceptable salt thereof.

57. A compound of formula (I') or (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-56, or a pharmaceutical composition according to any one of claims 1-10 with the proviso that the compound is not one selected from:


;


;


;


;

58. A compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-57, wherein such compounds of formula (I) show Kv7.2 EC_{50} <3μM and selectivity ratio Kv7.3_7.5/Kv7.2 >10x.

59. A pharmaceutical composition according to any one of claims 1-10, or a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 11-58, for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2 in a subject in need thereof.

60. A pharmaceutical pharmaceutical composition according to any one of claims 1-10, or a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 11-58, for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2 in a subject in need thereof, wherein the disorder, disease, or disability is selected from behavioral disorders, mood disorders,

neurodevelopmental disorders, intellectual disability, epilepsies, neurodegenerative diseases, pain, migraine, and tinnitus.

61. The pharmaceutical composition for use according to claim 60, wherein the disorder, disease, or disability is a behavioral disorder which is Attention Deficit Hyperactivity Disorder (ADHD).

62. The pharmaceutical composition for use according to claim 60, wherein the disorder, disease, or disability is a mood disorder which is depression.

63. The pharmaceutical composition for use according to claim 60, wherein the disorder, disease, or disability is a neurodevelopment disorder selected from autism spectrum disorder (ASD) and syndromic developmental disorders.

64. The pharmaceutical composition for use according to claim 60, wherein the disorder, disease, or disability is a syndromic developmental disorder selected from Dup15q syndrome (Dup15q), Fragile X syndrome (FXS) and Angelman syndrome.

65. The pharmaceutical composition for use according to claim 60, wherein the disorder, disease, or disability is an epilepsy selected from broad pediatric epilepsy, West syndrome, Ohtahara syndrome, and epileptic encephalopathy.

66. The pharmaceutical composition for use according to claim 60, wherein disorder, disease, or disability is a neurodegenerative disease selected from Alzheimer's disease, and motor neuron diseases.

67. The pharmaceutical composition for use according to any one of claims 59-66, for systemic or local administration such as oral, nasal, parenteral (as by intravenous (both bolus and infusion), intramuscular, or subcutaneous injection), transdermal, vaginal, buccal, rectal, or topical administration modes, intracisternally, intraperitoneally, as an oral or nasal spray, or as a liquid aerosol or dry powder for inhalation.

68. A compound according to any one of claims 11-58, or a pharmaceutical composition according to any one of claims 1-10 for use in therapy.

69. A compound according to any one of claims 11-58, or a pharmaceutical composition according to any one of claims 1-10, or a pharmaceutical composition for use according to any


one of claims 59-67, for the manufacture of a medicament for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2.

70. A method for the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2, which method comprises administering a therapeutically effective amount of a compound according to any one of claims 11-58, or a pharmaceutical composition according to any one of claims 1-10, or a pharmaceutical composition for use according to any one of claims 59-67.


71. A kit for use in the therapeutic and/or prophylactic treatment of a disorder, disease, or disability associated with Kv7.2 comprising:

a) a compound according to any one of claims 11-58, or a pharmaceutical composition according to any one of claims 1-10, or a pharmaceutical composition for use according to any one of claims 59-67; and
b) instructions for use.


72. A process for the preparation of a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-58, wherein the urea formation comprises the reactions:




or



or




or



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein.

73. A process for the preparation of a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 72, wherein R^1 is selected from 7-12 membered heterocycloalkyl, cyano, halogen, halo$C_{1\text{-}6}$alkyl, and 5 membered heteroaryl.

74. A process for the preparation of a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-58, wherein the process comprises the following reaction step:




wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein.

75. A process for the preparation of a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof, according to claim 74, wherein R^1 is selected from

haloC$_{1-6}$alkoxy, C$_{1-6}$alkoxy, 4-6 membered heterocyclyloxy, and C$_{3-5}$cycloalkylC$_{1-6}$alkoxy and R^2 and R^3 are hydrogen.

76. A process for the preparation of a compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof, according to any one of claims 11-58, wherein the process comprises the reactions of the following reaction steps:



wherein R^1, R^2, R^3, n, R^4, R^5 and R^6 are as defined herein.

77. A process for the preparation of a compound of formula (I), or a solvate or pharmaceutically acceptable salt thereof, according to claim 76, wherein R^1 is selected from haloC$_{1-6}$alkoxy, C$_{1-6}$alkoxy, 4-6 membered heterocyclyloxy, C$_{3-5}$cycloalkylC$_{1-6}$alkoxy, or cyanoC$_{1-6}$alkoxy, and R^2 is hydroxyC$_{1-6}$alkyl and R^3 is hydrogen.

78. A compound of formula (I), or a solvate or a pharmaceutically acceptable salt thereof according to any one of claims 11-58, when manufactured according to a process according to any one of claims 72-77.